ALDH1 expression correlates with favorable prognosis in ovarian cancers

Modern Pathology

Volumn 22, Issue 6, 2009, Pages 817-823

  Chang, Bin ^a,b,d   Liu, Guangzhi ^a,d   Xue, Fengxia ^a   Rosen, Daniel G ^c   Xiao, Lianchun ^a   Wang, Xuemei ^a   Liu, Jinsong ^a,d  

^a UNIVERSITY OF TEXAS   (United States)

^b SHIHEZI UNIVERSITY   (China)

^c BAYLOR COLLEGE OF MEDICINE   (United States)

^d UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

ALDH1; Immunohistochemistry; Ovarian cancer; Prognosis

Indexed keywords

ALDEHYDE DEHYDROGENASE; CISPLATIN; FLUOROURACIL; FOLINIC ACID; MELPHALAN;

ADULT; AGED; ARTICLE; CANCER ADJUVANT THERAPY; CANCER SURVIVAL; CELLULAR DISTRIBUTION; CONTROLLED STUDY; DISEASE FREE SURVIVAL; DRUG RESPONSE; EARLY CANCER; ENDOMETRIOID CARCINOMA; ENZYME LOCALIZATION; FEMALE; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; OVARY CARCINOMA; OVERALL SURVIVAL; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; SURVIVAL RATE; SURVIVAL TIME; TISSUE MICROARRAY;

ADULT; AGED; AGED, 80 AND OVER; ALDEHYDE DEHYDROGENASE; ANTINEOPLASTIC AGENTS; DRUG RESISTANCE, NEOPLASM; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; ISOENZYMES; KAPLAN-MEIERS ESTIMATE; MIDDLE AGED; NEOPLASM STAGING; OVARIAN NEOPLASMS; PROGNOSIS; TISSUE ARRAY ANALYSIS; TUMOR MARKERS, BIOLOGICAL;

EID: 67349255442     PISSN: 08933952     EISSN: 15300285     Source Type: Journal    
DOI: 10.1038/modpathol.2009.35     Document Type: Article

References (35)

1. Lindahl R. Aldehyde dehydrogenases and their role in carcinogenesis. Crit Rev Biochem Mol Biol 1992;27: 283-335.
2. Deitrich RA, Petersen D, Vasiliou V. Removal of acetaldehyde from the body. Novartis Found Symp 2007;285:23-40.
3. Ambroziak W, Pietruszko R. Human aldehyde dehy-drogenase. Activity with aldehyde metabolites of monoamines, diamines, and polyamines. J Biol Chem 1991;266:13011-13018.
4. Monder C, Purkaystha AR, Pietruszko R. Oxidation of the 17-aldol (20 beta hydroxy-21-aldehyde) intermediate of corticosteroid metabolism to hydroxy acids by homogeneous human liver aldehyde dehydrogenases. J Steroid Biochem 1982;17:41-49.
5. Duester G, Mic FA, Molotkov A. Cytosolic retinoid dehydrogenases govern ubiquitous metabolism of retinol to retinaldehyde followed by tissue-specific metabolism to retinoic acid. Chem Biol Interact 2003;143-144:201-210.
6. Ambroziak W, Izaguirre G, Pietruszko R. Metabolism of retinaldehyde and other aldehydes in soluble extracts of human liver and kidney. J Biol Chem 1999;274: 33366-33373.
7. Sladek NE. Human aldehyde dehydrogenases: potential pathological, pharmacological, and toxicological impact. J Biochem Mol Toxicol 2003;17:7-23.
8. Kastan MB, Schlaffer E, Russo JE, et al. Direct demonstration of elevated aldehyde dehydrogenase in human hematopoietic progenitor cells. Blood 1990; 75:1947-1950.
9. Storms RW, Trujillo AP, Springer JB, et al. Isolation of primitive human hematopoietic progenitors on the basis of aldehyde dehydrogenase activity. Proc Natl Acad Sci USA 1999;96:9118-9123.
10. Hess DA, Wirthlin L, Craft TP, et al. Selection based on CD133 and high aldehyde dehydrogenase activity isolates long-term reconstituting human hematopoietic stem cells. Blood 2006;107:2162-2169.
11. Cai J, Cheng A, Luo Y, et al. Membrane properties of rat embryonic multipotent neural stem cells. J Neurochem 2004;88:212-226.
12. Hess DA, Meyerrose TE, Wirthlin L, et al. Functional characterization of highly purified human hemato-poietic repopulating cells isolated according to aldehyde dehydrogenase activity. Blood 2004;104: 1648-1655.
13. Armstrong L, Stojkovic M, Dimmick I, et al. Pheno-typic characterization of murine primitive hemato-poietic progenitor cells isolated on basis of aldehyde dehydrogenase activity. Stem Cells 2004;22: 1142-1151.
14. Croker AK, Goodale D, Chu J, et al. High aldehyde dehydrogenase and expression of cancer stem cell markers selects for breast cancer cells with enhanced malignant and metastatic ability. J Cell Mol Med; 4 August 2008 (e-pub ahead of print).
15. Ginestier C, Hur MH, Charafe-Jauffret E, et al. ALDH1 is a marker of normal and malignant human mammary stem cells and a predictor of poor clinical outcome. Cell Stem Cell 2007;1:555-567.
16. Pearce DJ, Taussig D, Simpson C, et al. Characterization of cells with a high aldehyde dehydrogenase activity from cord blood and acute myeloid leukemia samples. Stem Cells 2005;23:752-760.
17. Ma S, Chan KW, Lee TK, et al. Aldehyde dehydrogen-ase discriminates the CD133 liver cancer stem cell populations. Mol Cancer Res 2008;6:1146-1153.
18. Clarke MF, Dick JE, Dirks PB, et al. Cancer stem cells - perspectives on current status and future directions: AACR workshop on cancer stem cells. Cancer Res 2006;66:9339-9344.
19. Polyak K. Breast cancer stem cells: a case of mistaken identity? Stem Cell Rev 2007;3:107-109.
20. Fillmore C, Kuperwasser C. Human breast cancer stem cell markers CD44 and CD24: enriching for cells with functional properties in mice or in man? Breast Cancer Res 2007;9:303.
21. Shipitsin M, Campbell LL, Argani P, et al. Molecular definition of breast tumor heterogeneity. Cancer Cell 2007;11:259-273.
22. Levi BP, Yilmaz OH, Duester G, et al. Aldehyde dehydrogenase 1a1 is dispensable for stem cell function in the mouse hematopoietic and nervous systems. Blood 2009;113:1670-1680.
23. Jemal A, Siegel R, Ward E, et al. Cancer statistics, 2008. CA Cancer J Clin 2008;58:71-96.
24. Scully RE. World Health Organization classification and nomenclature of ovarian cancer. Natl Cancer Inst Monogr 1975;42:5-7.
25. Russell P. The pathological assessment of ovarian neoplasms. I: introduction to the common 'epithelial' tumours and analysis of benign 'epithelial' tumours. Pathology 1979;11:5-26.
26. Russell P. The pathological assessment of ovarian neoplasms. II: the proliferating 'epithelial' tumours. Pathology 1979;11:251-282.
27. Russell P. The pathological assessment of ovarian neoplasms. III: the malignant 'epithelial' tumours. Pathology 1979;11:493-532.
28. Shepherd JH. Revised FIGO staging for gynaecological cancer. Br J Obstet Gynaecol 1989;96:889-892.
29. Malpica A, Deavers MT, Lu K, et al. Grading ovarian serous carcinoma using a two-tier system. Am J Surg Pathol 2004;28:496-504.
30. Rustin GJ, Nelstrop AE, Crawford M, et al. Phase II trial of oral altretamine for relapsed ovarian carcinoma: evaluation of defining response by serum CA125. J Clin Oncol 1997;15:172-176.
31. Armstrong DK. Relapsed ovarian cancer: challenges and management strategies for a chronic disease. Oncologist 2002;7(Suppl 5):20-28.
32. Rustin GJ, Nelstrop AE, Tuxen MK, et al. Defining progression of ovarian carcinoma during follow-up according to CA 125: a North Thames Ovary Group Study. Ann Oncol 1996;7:361-364.
33. Rosen DG, Yang G, Deavers MT, et al. Cyclin E expression is correlated with tumor progression and predicts a poor prognosis in patients with ovarian carcinoma. Cancer 2006;106:1925-1932.
34. Bradfute SB, Graubert TA, Goodell MA. Roles of Sca-1 in hematopoietic stem/progenitor cell function. Exp Hematol 2005;33:836-843.
35. Burger PE, Xiong X, Coetzee S, et al. Sca-1 expression identifies stem cells in the proximal region of prostatic ducts with high capacity to reconstitute prostatic tissue. Proc Natl Acad Sci USA 2005;102: 7180-7185.